luteosyl 0, 075 mg/ml solution for injection for cattle and pigs 0, 075 mg/ml
laboratorios syva, s.a.u. - д - Клопростенола - инжекционен разтвор - 0, 075 mg/ml - говеда, свине
mamifort
laboratorios syva, s.a.u. - Амоксицилин (както и натрий), Клоксациллин (натрий) - интрамамарна суспензия - 75 mg/8 g; 200 mg/8 g - кози, крави, овце
marbosyva 100 mg/ml инжекционен разтвор за говеда и прасета (свине) 100 mg/ml
laboratorios syva, s.a.u. - Марбофлоксацин - инжекционен разтвор - 100 mg/ml - говеда, прасета
syva bax
laboratorios syva, s.a. - clostr. perfringes анатоксина, тип А, b, c и d; clostr. septicum; clostridium нов, тип Б; с clostridium tetani; с clostridium sordellii; с clostridium chauvoei - инжекционна суспензия - 0.3 iu α; 10 iu β, 5 iu ε; 2.5 iu α; 3.5 iu α; 2.5 iu; 100% защита при контролни животни; 100% защита при контролни животни - биволи, говеда, зайци, кози, овце, прасета
syvadox 10 % 100 mg/ml
laboratorios syva, s.a.u. - Доксициклин (като доксициклин гиклат) - перорален разтвор - 100 mg/ml - прасета, птици
syvaquinol - 100 injectable solution 100 mg/ml
laboratorios syva, s.a. - Энрофлоксацин - инжекционен разтвор - 100 mg/ml - говеда, прасета
meganyl 50 mg/ml инжекционен разтвор за говеда, прасета и коне/ meganyl 50 mg/ml solution for injection for cattle, pigs and hor
laboratorios syva, s.a.u - flunixin - инжекционен разтвор - 50 mg/ml - говеда, коне, прасета
troxxan 100 mg/ml solution for injection for cattle, pigs and sheep 100 mg/ml
laboratorios syva, s.a.u - Тулатромицин - инжекционен разтвор - 100 mg/ml - говеда, овце, свине
troxxan 25 mg/ml solution for injection for pigs/ troxxan 25 mg/ml инжекционен разтвор за свине 25 mg/ml
laboratorios syva, s.a.u. - Тулатромицин - инжекционен разтвор - 25 mg/ml - прасета
tyenne
fresenius kabi deutschland gmbh - тоцилизумаб - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - Имуносупресори - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.